title: A double-blind comparative study of remoxipride and haloperidol in schizophrenic and schizophreniform disorders.
abstract: The antipsychotic effect of remoxipride was compared to that of haloperidol in a randomized double-blind study with parallel group design comprising 98 patients with schizophrenia or schizophreniform disorder according to DSM-III. After a 3-7 day placebo washout period, patients received either 150-600 mg of remoxipride or 5-20 mg of haloperidol daily for 6 weeks. No significant differences in efficacy were found between the two treatments. Treatment-emergent checklist symptoms such as hypokinesia, rigidity, and tremor occurred more frequently and were more severe during haloperidol than during remoxipride treatment despite a significantly higher concurrent use of anticholinergic drugs in the haloperidol group. Haloperidol-treated patients reported greater increases in sleep and salivation than remoxipride-treated patients. Shoulder shaking and tremor were reported as occurring more frequently in the haloperidol group according to the Simpson and Angus rating scale for extrapyramidal symptoms. In summary, the two drugs seemed to be equally efficacious, though the tolerability profile favoured remoxipride.
authors.affiliation: Hospital Erasme, University Clinics of Brussels, Belgium.
authors.forename: J
authors.initials: J
authors.lastname: Mendlewicz
authors.forename: E
authors.initials: E
authors.lastname: de Bleeker
authors.forename: P
authors.initials: P
authors.lastname: Cosyns
authors.forename: G
authors.initials: G
authors.lastname: Deleu
authors.forename: F
authors.initials: F
authors.lastname: Lotstra
authors.forename: A
authors.initials: A
authors.lastname: Masson
authors.forename: C
authors.initials: C
authors.lastname: Mertens
authors.forename: M
authors.initials: M
authors.lastname: Parent
authors.forename: J
authors.initials: J
authors.lastname: Peuskens
authors.forename: E
authors.initials: E
authors.lastname: Suy
mesh_terms: D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001480:Basal Ganglia Diseases / Q000209:etiology; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination; D011569:Psychiatric Status Rating Scales; D011618:Psychotic Disorders / Q000188:drug therapy*; D017330:Remoxipride; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology
chemical_list: D014150:Antipsychotic Agents; D001549:Benzamides; D017330:Remoxipride; D006220:Haloperidol